24AUG

Gavi funds vaccines made in Africa

2 min read

17:07UTC

Gavi approved an extra $189 million for African vaccine manufacturing on 2 July, with $139 million to buy Africa-made vaccines and a first disbursement expected before year-end.

← Back to Guatemala's measles outbreak outgrew Mexico Jump to analysis ↓

ScienceDeveloping

Key takeaway

Gavi earmarked $139 million for Africa-made vaccines, its first direct funding to African manufacturers.

GAVI, the vaccine-financing alliance, approved an extra $189 million for the African Vaccine Manufacturing Accelerator (AVMA) at a board meeting that closed on Thursday 2 July, on top of the programme's existing $1 billion ¹. Of the new money, $139 million is earmarked to buy vaccines made in Africa, with the first cash expected to reach an African manufacturer in the second half of 2026, a first for the scheme. The board also set Gavi 6.0 targets for 2026 to 2030: reach 500 million more children and prevent an estimated 8 to 9 million deaths.

GAVI's approval landed the same fortnight the African Union pledged $910 million toward the Ebola response and Africa CDC won direct access to the World Bank-hosted Pandemic Fund , the continent assembling its own response money. An African plant still needs the technology transfer and sample access that the stalled PABS annex is meant to guarantee, so the money approved by GAVI and the deadlock in Geneva are two ends of one problem. Africa can now finance the plant; what it lacks is the legal right to make and keep what comes out of it.

Deep Analysis

In plain English

Gavi is a global vaccine-buying alliance that pools money from governments and donors to make vaccines cheaper and more available in lower-income countries. This $189 million top-up specifically backs vaccine factories being built in Africa, rather than paying to import vaccines made elsewhere, which is what usually happens today. Shorter supply chains mean less dependence on whichever country happens to have spare manufacturing capacity during the next outbreak. The money won't move immediately. Gavi expects the first payments to manufacturers in the second half of 2026, so this is a bet on future capacity rather than an immediate supply fix for the current Ebola outbreak.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: The African Union's 2021 target of manufacturing 60% of the continent's vaccines locally by 2040, adopted after COVID-19 exposed near-total import dependence, is the pledge AVMA's extra $189 million is meant to advance, with $139 million of it earmarked specifically for doses made on the continent rather than imported.

Counter-parallel: COVAX, the pooled procurement mechanism built for COVID-19, abandoned its own manufacturing-transfer ambitions by 2023 after spending most of its budget buying finished doses from Northern manufacturers instead of building African production lines, the outcome AVMA's structure is explicitly designed to avoid repeating.

Of GAVI's new $189 million, $139 million is ring-fenced for Africa-made vaccines specifically, on top of the programme's existing $1 billion; first disbursements are expected in the second half of 2026, meaning manufacturers will not see cash before this funding round translates into production contracts.

Structurally, AVMA is a supply-side subsidy: it pays manufacturers to build and hold capacity regardless of whether an order materialises. That contrasts with the US Biomedical Advanced Research and Development Authority's model, which pays through advance-purchase commitments tied to a specific pathogen and delivery date.

Supply-side funding like AVMA's builds capacity that can pivot across diseases; demand-side funding like BARDA's builds capacity faster for one named threat but leaves it idle once that threat passes.

Sources:Tech Times

Mentions:GAVI →Pandemic Fund →African Union →Africa CDC →Geneva →World Bank →CDC →African Vaccine Manufacturing Accelerator →

First Reported In

Update #9 · Ebola's toolkit arrives, outbreak climbs

Tech Times· 5 Jul 2026

Read original →

Causes and effects

Caused by

Africa CDC wins direct pandemic funding

The African Union's $910m Ebola pledge the same fortnight shows the continent assembling its own response and manufacturing money alongside Gavi's.

Occurred 17 Jun 2026

Read story →

This Event

Gavi funds vaccines made in Africa

Gavi's money lets Africa finance vaccine plants, though the sample and technology access to fill them still hinges on the stalled PABS annex.

Led to

PABS annex slips a fourth deadline

Gavi's manufacturing funding still lacks the annex guarantee the deferred PABS text was meant to provide.

Occurred 17 Jul 2026

Read story →

Different Perspectives

UK Health Security Agency

UKHSA said egg consumption remains the strongest signal in its 207-case Salmonella Enteritidis investigation. The genomic cluster and 38% hospitalisation among people with available information make exposure identification a public-health priority.

GLEWS+

GLEWS+ assessed spillover risk from clade B MERS in Nile Basin camels as high if the clade establishes, while rating evidence for spread in camel populations low confidence. The joint assessment makes whole-genome sequencing the next test of the threat.

WHO Regional Office for Africa

WHO's Africa office said transmission in DR Congo is outpacing control efforts after laboratory capacity reached 19 sites and treatment capacity exceeded 1,300 beds. The assessment puts access, insecurity, community deaths and late care-seeking ahead of a simple equipment shortage.

People in Guatemala

Guatemala's population now carries the region's largest reported measles burden, with 30,371 confirmed cases and 26 deaths. The scale shifts practical attention from the Mexico-centred frame that followed the World Cup's travel consequences.

Pan American Health Organization

PAHO rated regional measles risk very high after recording 47,459 confirmed cases and 44 deaths through week 28. It names vaccination coverage, accumulated susceptibles and mass gatherings with broad international participation as general risk factors.

Chinese health authorities

China reported three human H9N2 cases to WHO between 10 and 16 July: two four-year-olds recovered, a 44-year-old man remains in intensive care, the first severity signal in a cluster that has produced 173 cases and 2 deaths globally since 2015. The subtype is distinct from the H5N1 series this topic otherwise tracks.